L-BAIBA Identified as Key Exercise Signal for Muscle Adaptation and Diabetes Protection
Researchers at the University of Leeds have identified L-β-aminoisobutyric acid (L-BAIBA) as a critical metabolite that mediates skeletal muscle adaptation to exercise. Published in Nature Communications, the study demonstrates that L-BAIBA, produced via the PGC1α-BAIBA-PPARδ axis, enhances muscle fiber remodeling, mitochondrial function, and contractile force in mice. In humans, plasma L-BAIBA levels correlate with aerobic fitness and increase with endurance training. The findings suggest L-BAIBA could serve as a therapeutic target for muscle dysfunction in type 2 diabetes, potentially mimicking exercise benefits in patients unable to train.
Key points
- L-BAIBA is the primary enantiomer responsible for muscle adaptation, acting through the Mas-related G-protein coupled receptor D.
- Mice given L-BAIBA showed improved voluntary wheel running performance, increased muscle mass, and enhanced mitochondrial respiratory capacity.
- Knockdown of the biosynthetic enzyme 4-aminobutyrate aminotransferase in mouse muscle impaired exercise-induced adaptations.
- In a mouse model of type 2 diabetes, L-BAIBA treatment mitigated muscle dysfunction and improved metabolic markers.
- Human studies confirm that L-BAIBA levels rise with endurance training and correlate with aerobic fitness.
Background
This research builds on 2014 findings that BAIBA influences fat-burning and hepatic metabolism. Recent archive coverage highlights ongoing efforts to preserve muscle function in aging and disease, such as the LASSS compound for age-related muscle loss and studies on long COVID muscle changes. The current study expands the role of BAIBA from a systemic metabolite to a direct regulator of skeletal muscle phenotype.
How outlets are covering it
The primary source, Nature, provides detailed mechanistic data on the PGC1α-BAIBA-PPARδ axis and specific molecular markers in mice and human myotubes. The University of Leeds press release emphasizes the therapeutic potential for type 2 diabetes and quotes Professor Lee Roberts on the clinical implications. Genetic Engineering and Biotechnology News highlights the broader applicability to conditions like cancer cachexia and sarcopenia, noting that BAIBA is already available as a supplement. Diabetes In Control focuses on the potential for new drugs inspired by exercise myokines. All sources agree on the significance of L-BAIBA but vary in emphasis: Nature focuses on molecular mechanisms, while secondary sources highlight clinical translation and therapeutic applications.
Why it matters
Understanding the molecular signals that drive exercise adaptation could lead to 'exercise mimetics' for individuals unable to exercise due to illness or disability. This is particularly relevant for type 2 diabetes, where muscle weakness limits physical activity, creating a vicious cycle of metabolic dysfunction. Identifying L-BAIBA as a key mediator offers a potential pharmacological target to improve muscle health and quality of life.
What to watch
Future research will focus on clinical trials to test BAIBA as a therapeutic intervention for muscle atrophy and dysfunction in conditions like type 2 diabetes, heart failure, and sarcopenia. The team also plans to investigate whether BAIBA can improve exercise capacity and quality of life in these clinical populations.
- The metabokine β-aminoisobutyric acid mediates exercise performance and skeletal muscle adaptation through a PGC1α-BAIBA-PPARδ axis Nature
- A molecule released during exercise may help protect muscles weakened by type 2 diabetes Medical Xpress
- Myokines and Diabetes: Could Exercise Inspire New Drugs? Diabetes In Control
- Muscle-boosting molecule released during exercise University of Leeds
- Exercise-Boosting Molecule May Help Improve Muscle Health in Type 2 Diabetes Genetic Engineering and Biotechnology News
Want the full story? Read the original reporting
Read on Nature